Aelis Farma SA (EPA:AELIS)
France · Delayed Price · Currency is EUR 1.020
-0.010 (-0.97%)
Jul 21, 2026, 5:35 PM CET
Aelis Farma Company Description
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.
The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases.
Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Aelis Farma SA
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Pier Piazza |
Contact Details
Address: 1 rue Lafaurie de Monbadon Bordeaux, 33000 France | |
| Phone | 33 5 54 54 23 27 |
| Website | aelisfarma.com |
Stock Details
| Ticker Symbol | AELIS |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0014007ZB4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pier Vincenzo Piazza M.D., Ph.D. | Chief Executive Officer and Director |
| Stephanie Monlezun | Chief Operating Officer |